Swine Biomedical Research Facility for gnotobiotic, transgenic and translational medicine

猪限生、转基因和转化医学生物医学研究设施

基本信息

项目摘要

The overall goal of this project is to design, construct and outfit a swine biomedical research facility on the campus of the fourth ranked College of Veterinary Medicine in the United States with ready access to trained veterinary specialists and state of the art biomedical (e.g. MRI, CT and nuclear medicine) facilities. The facility will provide additional high-quality space for biomedical research by NIH funded faculty from NC State University, Duke University and the University of North Carolina. The design and construction of the swine biomedical research facility will feature a free-standing masonry and steel building that will house the production and care of gnotobiotic and gene-edited swine, as well as state-of-the-art procedures (surgical, telemetry, arthroscopy, endoscopy). In addition, the unit includes flexible space that can accommodate pregnant and non-pregnant sows, and farrowing facilities to generate needed gene edited progeny from our own lines as well as those obtained from the NIH-supported NSRRC. Procedural space will provide a sterile surgery suite (two tables) to accommodate an increasing bioengineering need for endoscopic and arthroscopic procedures. The building will be placed immediately adjacent to space (referred to as the G20 facility) previously created for the use of severe combined immunodeficiency and other gene edited miniature or juvenile pigs (G20 OD020279) to allow for shared use of the space when possible. The proposed facility has been designed to maximize synergy and minimize overlap with the G20 space. Combined they will give us a high degree of flexibility and will allow us to conduct a broad range of research thus having a broad impact across multiple NIH Centers/Institutes. This project team is uniquely situated to drive the design and development of this facility and the expansion of this program. By serving in leadership roles within the College of Veterinary Medicine and NC State University we have the ability to provide access to the veterinary college biomedical campus, the research animal facilities and the state-of-the-art equipment in the tertiary care veterinary hospital. Our team of investigators has comparative medicine expertise and an extensive collaborative network with biomedical researchers at Duke and the University of North Carolina. As a team, we have successfully managed infrastructure grants, such as the expansion of facilities for housing and studying transgenic and non-transgenic miniature pigs (G20 OD020279) and building projects including a 20,000 square foot wet lab and GMP lab space.
该项目的总体目标是设计、建造和装备猪生物医学研究设施 美国排名第四的兽医学院校园,可方便地访问 训练有素的兽医专家和最先进的生物医学(例如 MRI、CT 和核医学)设施。 该设施将为 NIH 资助的北卡罗来纳州教师的生物医学研究提供额外的高质量空间 州立大学、杜克大学和北卡罗来纳大学。 猪生物医学研究设施的设计和建造将设有一个独立的 砖石和钢结构建筑将用于生产和护理无菌猪和基因编辑猪, 以及最先进的手术(手术、遥测、关节镜、内窥镜)。此外,该单元还包括 可容纳怀孕和非怀孕母猪的灵活空间以及产仔设施 需要从我们自己的品系以及从 NIH 支持的 NSRRC 获得的后代中进行基因编辑。 手术空间将提供无菌手术室(两张桌子),以适应不断增加的手术室 生物工程需要内窥镜和关节镜手术。该建筑将立即安置 毗邻空间(称为 G20 设施),之前为使用严格的联合设施而创建 免疫缺陷和其他基因编辑的小型猪或幼年猪(G20 OD020279)以允许共享使用 尽可能的空间。拟议设施的设计旨在最大限度地发挥协同作用并最大限度地减少 与 G20 空间重叠。它们结合起来将为我们提供高度的灵活性,并使我们能够进行 研究范围广泛,因此对多个 NIH 中心/研究所产生广泛影响。 该项目团队具有独特的优势,可以推动该设施的设计和开发以及 该计划的扩展。在兽医学院和北卡罗来纳州担任领导职务 州立大学我们有能力提供进入兽医学院生物医学校区的机会, 三级兽医医院的研究动物设施和最先进的设备。我们的 研究人员团队拥有比较医学专业知识和广泛的合作网络 杜克大学和北卡罗来纳大学的生物医学研究人员。作为一个团队,我们成功地 管理基础设施赠款,例如扩大住房和研究转基因和 非转基因小型猪 (G20 OD020279) 和建筑项目,包括 20,000 平方英尺的湿实验室 和 GMP 实验室空间。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KATHRYN M MEURS其他文献

KATHRYN M MEURS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KATHRYN M MEURS', 18)}}的其他基金

CANINE MODELS OF FAMILIAL DILATED CARDIOMYOPATHY
家族性扩张型心肌病的犬模型
  • 批准号:
    2451975
  • 财政年份:
    1995
  • 资助金额:
    $ 627.75万
  • 项目类别:
CANINE MODELS OF FAMILIAL DILATED CARDIOMYOPATHY
家族性扩张型心肌病的犬模型
  • 批准号:
    2702078
  • 财政年份:
    1995
  • 资助金额:
    $ 627.75万
  • 项目类别:
CANINE MODELS OF FAMILIAL DILATED CARDIOMYOPATHY
家族性扩张型心肌病的犬模型
  • 批准号:
    2910473
  • 财政年份:
    1995
  • 资助金额:
    $ 627.75万
  • 项目类别:
CANINE MODELS OF FAMILIAL DILATED CARDIOMYOPATHY
家族性扩张型心肌病的犬模型
  • 批准号:
    2211393
  • 财政年份:
    1995
  • 资助金额:
    $ 627.75万
  • 项目类别:
CANINE MODELS OF FAMILIAL DILATED CARDIOMYOPATHY
家族性扩张型心肌病的犬模型
  • 批准号:
    2211395
  • 财政年份:
    1995
  • 资助金额:
    $ 627.75万
  • 项目类别:
CANINE MODELS OF FAMILIAL DILATED CARDIOMYOPATHY
家族性扩张型心肌病的犬模型
  • 批准号:
    2415469
  • 财政年份:
    1995
  • 资助金额:
    $ 627.75万
  • 项目类别:

相似海外基金

High-dimensional single-cell mapping to define immune signatures of cytomegalovirus-associated rejection in cardiac transplantation
高维单细胞图谱定义心脏移植中巨细胞病毒相关排斥反应的免疫特征
  • 批准号:
    10816183
  • 财政年份:
    2023
  • 资助金额:
    $ 627.75万
  • 项目类别:
Phthalate Exposure and Mechanisms of Action in the Neonatal Intensive Care Unit
新生儿重症监护病房中邻苯二甲酸盐的暴露及其作用机制
  • 批准号:
    10736301
  • 财政年份:
    2023
  • 资助金额:
    $ 627.75万
  • 项目类别:
Mentoring Emerging Researchers at CHLA (MERCH-LA)
指导 CHLA (MERCH-LA) 的新兴研究人员
  • 批准号:
    10797938
  • 财政年份:
    2023
  • 资助金额:
    $ 627.75万
  • 项目类别:
Shigella Conjugate Vaccine (SCV4) Development, Characterization, and Pre-clinical Evaluation
志贺氏菌结合疫苗 (SCV4) 的开发、表征和临床前评估
  • 批准号:
    10704325
  • 财政年份:
    2023
  • 资助金额:
    $ 627.75万
  • 项目类别:
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms
开发一类针对碳青霉烯类耐药革兰氏阴性生物的新型肽抗生素
  • 批准号:
    10674131
  • 财政年份:
    2023
  • 资助金额:
    $ 627.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了